Sona Nanotech Withdraws Health Canada Application For COVID-19 Test Due To Feedback From Regulator

In what is a major blow to shareholders of Sona Nanotech (CSE: SONA), the company this afternoon announced that it has withdrawn its rapid COVID-19 antigen application from Health Canada based on feedback it has received from the regulatory agency. The move is being conducted “in order to obtain more clinical data to augment its submission.”

While the application for approval has been withdrawn, the company indicate that it will “continue to pursue approval” of the test from the agency, which is a nasal swab-type test. Sona is also reportedly continuing to validate its saliva-based version of the rapid test. Now, the company will be looking to conduct a large scale trial for this saliva-based test.

Despite withdrawing its application for an interim order authorization from Health Canada for the marketing of its test, the company continued to state within the news release that it’s “COVID-19 antigen test offers results within 15 minutes.” The company also reiterated that testing has shown an agreement with RT-PCR tests 85% of the time, along with 96% sensitivity.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Commenting on the withdrawn application, President and chief scientific officer Darren Rowles stated, “The regulatory approval path for antigen tests is new with evolving guidelines and Sona’s test is unique, creating a challenging environment for test developers and regulators alike.” He then followed up that statement by indicating the company is committed to obtaining the data required.

A timeframe for the required data collection to proceed with Health Canada authorizations was not provided by the company. The company has indicated that it intends to resubmit its application as quickly as possible

Sona Nanotech last traded at $3.11 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Giant Got Crushed… Now It’s the Cheapest Major | Kinross Gold’s Q3 Earnings

Why I’m Still Bullish on Gold Below $3,900 | Wes Hanson – Thunder Gold

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Quebec Health Inadvertently Tweets COVID Update Linked To Foot Fetish Porn Video

As the country faces another wave of rising COVID-19 cases, Quebec’s Ministry of Health and...

Tuesday, April 19, 2022, 10:14:00 AM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

Kontrol Energy Enters Exclusive Distribution Arrangement Across First Responder And Public Transport Industries

Kontrol Energy Corp (CSE: KNR) this morning announced that it has entered into an exclusive...

Tuesday, December 1, 2020, 07:49:59 AM

Medicago, GSK Report 71% Efficacy Rate From Plant-Based COVID-19 Vaccine Study

Quebec-based biopharmaceutical firm Medicago and healthcare conglomerate GlaxoSmithKline (NYSE: GSK) announce today the results from...

Tuesday, December 7, 2021, 11:21:00 AM

Sona Nanotech’s Rapid Antigen Test Approved For Sale In Europe Via CE Mark Approval

Sona Nanotech (CSE: SONA) has been granted CE Mark status for its rapid COVID-19 antigen...

Thursday, December 31, 2020, 09:33:17 AM